Posted on 12/21/18
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its . . .
Posted on 12/20/18
Ayala Pharmaceuticals Signs Deal to Develop and Commercialize AL102 in Combination with BCMA Targeting Agents in Multiple Myeloma
REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, announced today that it entered into an . . .
Posted on 12/20/18
Johnson & Johnson: Caution Here
Summary Johnson & Johnson has seen harsh times as an old asbestos claim is playing up again. Shares have been hit hard as this times it . . .
Posted on 12/20/18
Why I Had To Buy Johnson & Johnson
Summary Johnson & Johnson is truly one of the most beloved dividend growth stocks and a cornerstone of many portfolios. The story from Reuters alleging the . . .
Posted on 12/20/18
Johnson & Johnson: Weak Sign
Summary JNJ continues to face escalating liability risk due to talc cancer lawsuits. The authorized $5 billion share buyback reduces confidence in the stock. Even after . . .
Posted on 12/20/18
Merck To Acquire Antelliq Group For Animal Monitoring Tech
Merck (MRK) announced it has agreed to acquire Antelliq Group for $3.72 billion in total consideration and debt assumption.
Posted on 12/20/18
Strongbridge Biopharma Closes Transaction with Novo Nordisk
DUBLIN, Ireland and TREVOSE, Pa., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and . . .
Posted on 12/19/18
ADMA Biologics Provides Regulatory Update for BIVIGAM
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA), announces that as of the time of this press . . .
Posted on 12/19/18
Johnson & Johnson: Caution Here
Summary Johnson & Johnson has seen harsh times as an old asbestos claim is playing up again. Shares have been hit hard as this times it . . .
Posted on 12/19/18
How Safe Is Johnson & Johnson's Dividend?
Summary Johnson & Johnson is both a Dividend Aristocrat and a Dividend King, and is one of the most well-known dividend growth stocks in the public . . .
Posted on 12/19/18
3 Reasons Why Pfizer's Latest Dividend Hike Is Better Than You Might Think
Congratulations, Pfizer (NYSE:PFE) shareholders. You just got a nice raise.Last week, the big pharma company announced that its board of directors had approved an increase in . . .
Posted on 12/19/18
Celgene's Stock Is Fairly Valued Even In Worst-Case Revlimid Scenario
SummaryCelgene increased 2018 revenue expectations for the second time this year as strong growth continues.Celgene's rock-bottom Forward P/E of 6.59x and PEG Ratio of 0.39x help . . .
Posted on 12/19/18
Outlook Therapeutics Provides Business Update
CRANBURY, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its fiscal year ended . . .
Posted on 12/18/18
Johnson & Johnson: Overblown Sell-Off On Bad News Brings Great Buying Opportunity
SummaryReuters story causes sell-off for Johnson & Johnson Friday.Multiple analysts are backing up Johnson & Johnson, stating that the decline was overdone.A dramatic pullback opens up . . .
Posted on 12/18/18
What Do Johnson & Johnson And BP Have In Common?
Summary JNJ plunged 10% on Friday on the news that the company was aware of the presence of asbestos in its baby powder for decades. The . . .
Posted on 12/18/18
Johnson & Johnson Proves Its Psoriasis Drug Can Be A Big Contender
Summary Johnson & Johnson shows that its psoriasis drug Tremfya can definitely go toe to toe with Novartis' Cosentyx. Cosentyx was shown to have a rapid . . .
Posted on 12/18/18
Better Buy: Eli Lilly and Company vs. Merck & Co.
Pharmaceutical heavyweights Merck & Co. Inc. (NYSE:MRK) and Eli Lilly and Company(NYSE:LLY) are getting a lot of attention after outperforming the market by a mile in . . .
Posted on 12/18/18
Universal Health Services Announces Increase To Stock Repurchase Program
Universal Health Services, Inc. (NYSE: UHS) announced today that its Board of Directors authorized a $500 million increase to its stock repurchase program. This authorization will . . .
Posted on 12/17/18
Cancer Genetics Terminates Proposed Merger with NovellusDx
RUTHERFORD, N.J., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 12/17/18
Johnson & Johnson: Reuters Ripped Off The Band-Aid
SummaryReuters released a sobering report claiming that Johnson & Johnson had concealed knowledge that its baby powder contained asbestos and intentionally avoided disclosure.Regardless of whether or . . .
Posted on 12/16/18
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
WILMINGTON, Del. & SUZHOU, China--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the companies, through their respective subsidiaries, have entered into . . .
Posted on 12/15/18
Rite Aid Foundation’s KidCents Program Donates $50,000 to Hurley Children's Hospital
CAMP HILL, Pa.--(BUSINESS WIRE)--The Rite Aid Foundation announced today a grant of $50,000 to the Hurley Foundation, on behalf of Hurley Children’s Hospital in Flint, Mich., . . .
Posted on 12/13/18
Zoetis Announces Authorization of $2 Billion Share Repurchase Program
PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has authorized a $2 billion multi-year share repurchase program as part of its . . .
Posted on 12/13/18
The Medicines Company to Offer $150 Million of Convertible Notes
PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market . . .
Posted on 12/13/18
Marinus Pharmaceuticals Prices Public Offering of Common Stock
RADNOR, Pa., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced the pricing of an underwritten public offering of 12,000,000 shares of common . . .

